Per Ostlund analyst CRAIG HALLUM

Currently out of the existing stock ratings of Per Ostlund, 8 are a BUY (88.89%), 1 are a HOLD (11.11%).

Per Ostlund

Work Performance Price Targets & Ratings Chart

Analyst Per Ostlund, currently employed at CRAIG HALLUM, has had 68.75% of price targets met with an average potential upside of 35.62%, reached in 159 days on average.

Per Ostlund has documented 24 price targets and ratings displayed on 6 stocks. The coverage is on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on ICAD, icad inc at 16-May-2023.

Wall Street Analyst Per Ostlund

Analyst best performing recommendations are on ICAD (ICAD INC).
The best stock recommendation documented was for ICAD (ICAD INC) on 5/16/2023. The price target of $2.5 was fulfilled within 63 days with a profit of $1.36 (119.3%), with a performance score of 18.94.

Average potential price target upside

CEMI Chembio Diagnostics CDNA Caredx EXAS EXACT Sciences ICAD icad inc

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 22-Jul-2021

$7.5

5 years 4 months ago
(22-Jul-2021)

2/2 (100%)

$2.76 (58.23%)

256

Hold Since 03-Dec-2020

$10

$8

5 years 11 months 19 days ago
(03-Dec-2020)

0/3 (0%)

$2.49 (33.16%)

Hold Since 17-Jun-2020

$7

6 years 5 months 5 days ago
(17-Jun-2020)

2/2 (100%)

$-0.16 (-2.23%)

151

Buy Since 26-May-2020

$4

$21

6 years 5 months 5 days ago
(17-Jun-2020)

1/2 (50%)

$0.11 (2.83%)

15

$7

$9

6 years 5 months 5 days ago
(17-Jun-2020)

2/2 (100%)

$3.11 (79.95%)

317

Show more analysts

Stocks Per Ostlund covered previously. Scores are shown for active stocks only.

CE Celanese NTRA Natera

Please expand the browser size to see the chart

What Year was the first public recommendation made by Per Ostlund?

On 2015
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?